Literature DB >> 18228020

CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34- cells in childhood AML.

Tatsiana V Shman1, Uladzimir U Fedasenka, Valery P Savitski, Olga V Aleinikova.   

Abstract

In view of obscure clinical and biological significance of leukemic cells heterogeneity, we studied the efficacy of apoptosis, proliferation, and expression levels of the Bcl-2, MDR1, LRP, and BCRP genes in sorted CD34+ and CD34- subpopulations of childhood AML leukemic samples. In five out of nine cases, CD34+ cells were less sensitive to spontaneous apoptosis and had from 1.2- to 5.0-fold higher expression levels of Bcl-2 (eight of ten) and from 1.5- to 28.7-fold higher expression levels of MDR1 (eight of ten). The expression levels of the LRP gene were from 1.1- to 1.8-fold higher in CD34+ subpopulations (five of ten cases), and the expression levels of the BCRP gene were from 1.1- to 22.4-fold higher in CD34+ leukemic cells (six of ten). In all M4 cases, the expression levels of LRP were higher in the CD34- subpopulation. Significant differences in the patterns of genes expression between patients do not allow us to conclude that the CD34+ fractions have more resistant phenotype than the CD34- subpopulations. Nevertheless, distinctions between CD34+ and CD34- cells may lead to different chemosensitivities between leukemic subpopulations in vivo and may determine the alteration of the leukemic immunophenotype during treatment and in relapse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228020     DOI: 10.1007/s00277-008-0439-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

1.  Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.

Authors:  Paloma S Souza; James P Madigan; Jean-Pierre Gillet; Khyati Kapoor; Suresh V Ambudkar; Raquel C Maia; Michael M Gottesman; King Leung Fung
Journal:  Exp Cell Res       Date:  2015-06-19       Impact factor: 3.905

Review 2.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

3.  Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Authors:  Jia Rao; Duo-Rong Xu; Fei-Meng Zheng; Zi-Jie Long; Sheng-Shan Huang; Xing Wu; Wei-Hua Zhou; Ren-Wei Huang; Quentin Liu
Journal:  J Transl Med       Date:  2011-05-19       Impact factor: 5.531

Review 4.  Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Authors:  Takeo Nakanishi; Douglas D Ross
Journal:  Chin J Cancer       Date:  2011-11-18

5.  Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species.

Authors:  Monika A Papież; Wirginia Krzyściak; Krzysztof Szade; Karolina Bukowska-Straková; Magdalena Kozakowska; Karolina Hajduk; Beata Bystrowska; Jozef Dulak; Alicja Jozkowicz
Journal:  Drug Des Devel Ther       Date:  2016-02-04       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.